



Covid 19 – sustainable healthcare & laboratory infrastructures - consortium climate & health & prevention

Ivana Haluskova Balter

Medical and Scientific Consultant for Partnership, France

Abstract:

Bacteria, viruses, parasites and fungi that are resistant to drug cause 700,000 death each year. By 2050 superbugs inured to treatments could cause up to 10 million deaths annually and costs the global economy US\$100 trillion. (1)

AMR (antimicrobial) resistance is regarded given Covid -19 lesson again nowadays as a major threat to global public health. Pandemics brought to our attention use of antibiotics given ARDS, hospitalization, hospital acquired pneumonia and ventilator associated pneumonia where particularly in gram negative resistance to last line treatment observed thus framing health as a “global security issue”. as recent example previously Ebola, MERS,SRAS.

Cancer and diabetic (association with tuberculosis is known given immune lowered capacities in diabetic patients) given their “at risk “ groups and hospital frontline workers are most exposed to virus with high transmissibility and several approaches – plasma, treatment and vaccines under evaluation and review of regulatory bodies with several pending question given time from signal to action.

Scarification known from history in Asian countries , and later on discovery of vaccines to prevent diseases along with hygiene comes from ancient times but introduction of live attenuated vaccines mimicking natural course of diseases like measles, polio, rotavirus and BCG has been associated with much larger reduction of mortality than can be explained by the prevention of the targeted infections which is tested due given cross protection for frontline healthcare workers to confirm strong immunological rationale.

Covid 19 is showing even more profound manner strong need for awareness and education about immunity, diseases , vaccines, hygiene, sanitation, nutrition (immunity)Lack of education and other various reason hamper its adherence in many countries before Covid 19 observed causing outbreaks getting serious attention.

Biography:

Ivana Haluskova Balter is a Medical and cosmopolitan professional specialised in infectious diseases, internal medicine covering various therapeutic axes, certified in Immunology



and Pediatric, MBA vaccinology and years of clinical practise contributing to bring innovative science and diplomacy for global health. Lived multi-country medical “field “experience in Southeast Asia (India in particular), West/Central/East Europe. Speaking French, English, Russian, Italian, Czech, Slovak with notion of Mandarin. Over 15 years of experience in pharmaceutical research and development for European and USA companies (Director of R&D for new delivery platforms focused on children and elderly) for various therapeutic areas for adults and children including neurodegenerative diseases, infectious diseases and tropical diseases, metabolic diseases and orphan indications. Active member of French immunology society (SFI) administrative board and several international academic societies (focus on innovation of R&D reflecting immunology and genetic variability, role of immunologic approach for treatment and diagnostic, tackle problem of resistance for antimicrobials, antimalarial, antivirals etc). Member of advisory Health concern (India) and think tank group in order to attract attention to role of immunology, personalised and preventive medicine and accurate diagnostic and global cooperation in this area. Years of expertise to work globally within Europe, USA but recently more focused on BRICS - Asia (India in Particular) as a Medical advisor bringing new innovative concepts alive and getting them endorsed.

Publication of speakers:

1. Ivana haluskova balter et al., Vaccines to Tackle Antimicrobial Resistance”. Acta Scientific Microbiology 2.11 (2019): 78-79.
2. Ivana haluskova balter et al., Microbes, Immunity and Metabolism, Institute Pasteur Paris, 2017: Sep;12(2)

[Webinar on COVID-19 Vaccination | November 14, 2020 | Rome, Italy](#)

Citation: Ivana Haluskova Balter; Covid 19 – sustainable healthcare & laboratory infrastructures - consortium climate & health & prevention, COVID Vaccines 2020; November 14, 2020; Rome, Italy.